SCHEMBL1705802

SCHEMBL1705802

CCOC(=O)c1coc(Cn2ccc(C(C)=O)n2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.45
CYP1A2 P05177 2/20 0.40
KDM4E B2RXH2 4/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 5/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
NLRP3 Q96P20 1/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK1 P28482 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
JMJD6 Q6NYC1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707155 0.84 FPR2 (0.51) FPR2KMT2AMEN1NPC1RAB9A
SCHEMBL1706229 0.83 FPR2 (0.48) FPR2CYP1A2POLBALDH1A1KMT2A
SCHEMBL2685053 0.83 FPR2 (0.48) FPR2CYP1A2ALDH1A1KMT2AMEN1
SCHEMBL13254733 0.80 FPR2 (0.50) FPR2CYP1A2ALDH1A1KMT2AMEN1
SCHEMBL2685055 0.79 FPR2 (0.44) FPR2CYP1A2ALDH1A1KMT2AMEN1
SCHEMBL27882081 0.78 FPR2 (0.44) FPR2KMT2AMEN1NPC1RAB9A
SCHEMBL27882139 0.77 FPR2 (0.45) FPR2POLBALDH1A1KMT2AMEN1
SCHEMBL1167220 0.76 FPR2 (0.51) FPR2ALDH1A1KMT2AMEN1
SCHEMBL9714181 0.74 CYP1A2 (0.51) CYP1A2KDM4EPOLBALDH1A1KMT2A
SCHEMBL1705835 0.74 ALDH1A1 (0.38) CYP1A2KDM4EPOLBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 FPR2 156/4885CYP1A2 413/4885KDM4E 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.